Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fimasartan + chlorthalidone (Addpharma, Inc.)
- Development stage
- Unknown
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD-2321 + AD-2322 is a fixed-dose combination (FDC) drug regimen under development by Addpharma Inc. for the treatment of hypertension. The combination consists of fimasartan, a non-peptide angiotensin II receptor antagonist (ARB), and chlorthalidone, a thiazide-like diuretic. Fimasartan works by selectively blocking the Type-1 angiotensin II receptor (AT1), thereby inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Chlorthalidone acts by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the nephron, leading to increased excretion of sodium and water, which reduces extracellular fluid volume and blood pressure. The combination is being evaluated in Phase 1 clinical trials (e.g., NCT07312799) to assess pharmacokinetic interactions and safety in healthy adult volunteers.
- Other names
- fimasartan/amlodipine/chlorthalidone
02
Targets
AGTR2 (AT2)CA (Carbonic anhydrase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on fimasartan + chlorthalidone (Addpharma, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fimasartan + chlorthalidone (Addpharma, Inc.).